Clinical Trial Update: Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of RC48 plus carboplatin for HER2-expressing advanced ovarian cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• RC48 (disitamab vedotin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING